Compare SDA & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | CING |
|---|---|---|
| Founded | 2007 | 2012 |
| Country | China | United States |
| Employees | 544 | 14 |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 79.8M | 64.5M |
| IPO Year | N/A | N/A |
| Metric | SDA | CING |
|---|---|---|
| Price | $0.78 | $4.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | $4.75 | ★ $34.50 |
| AVG Volume (30 Days) | 110.4K | ★ 218.6K |
| Earning Date | 04-28-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $12.01 | N/A |
| Revenue Next Year | $15.55 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.47 | $3.16 |
| 52 Week High | $2.93 | $11.89 |
| Indicator | SDA | CING |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 51.94 |
| Support Level | N/A | $4.21 |
| Resistance Level | N/A | $5.15 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 83.23 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.
Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.